Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with Pheochromocytoma and Paraganglioma

Recruiting
18-99 years
All
Phase 1
30 participants needed
1 Location

Brief description of study

The purpose of this study is to learn if a special type of imaging drug, called a “radioactive tracer” can help doctors see sites of pheochromocytoma or paraganglioma more clearly when used with a procedure called Positron Emission Tomography/Computed Tomography (PET/CT).” Eligible participants will complete the following research procedures: • Up to 2 18F-FTT PET/CT scans: before starting a new treatment for pheochromocytoma or paraganglioma and 1-21 days after start of treatment (The second scan is OPTIONAL). • Optional research collection of tissue from a surgical specimen or clinical biopsy (if applicable). Participants who agree to the scan after treatment, may be in the study for up to 6 weeks. The active part of participation during this time will only include PET/CT scan visits. Participants will be asked for permission to store and use data related to your participation in this study for future use. Participants will be compensated up to $150.00 per FTT PET/CT scan for participation in the study, for a potential total of $300.00 if they are undergoing two scans.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pheochromocytoma and Paraganglioma
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 18 Sep 2024. Study ID: 851463

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center